Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Korro Bio (KRRO) EBITDA (2019 - 2025)

Korro Bio's EBITDA history spans 7 years, with the latest figure at -$50.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 132.71% year-over-year to -$50.0 million, compared with a TTM value of -$117.3 million through Dec 2025, down 40.81%, and an annual FY2025 reading of -$117.3 million, down 40.81% over the prior year.
  • EBITDA for Q4 2025 was -$50.0 million at Korro Bio, down from -$18.0 million in the prior quarter.
  • The five-year high for EBITDA was $5.8 million in Q4 2022, with the low at -$50.0 million in Q4 2025.
  • Average EBITDA over 5 years is -$21.3 million, with a median of -$20.9 million recorded in 2022.
  • Year-over-year, EBITDA skyrocketed 127.19% in 2022 and then plummeted 537.86% in 2023.
  • Tracing KRRO's EBITDA over 5 years: stood at -$21.4 million in 2021, then skyrocketed by 127.19% to $5.8 million in 2022, then plummeted by 537.86% to -$25.4 million in 2023, then increased by 15.44% to -$21.5 million in 2024, then plummeted by 132.71% to -$50.0 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's EBITDA are -$50.0 million (Q4 2025), -$18.0 million (Q3 2025), and -$25.9 million (Q2 2025).